The stock of Immunovant Inc (IMVT) has seen a -13.84% decrease in the past week, with a -14.13% drop in the past month, and a -22.30% decrease in the past quarter. The volatility ratio for the week is 5.18%, and the volatility levels for the past 30 days are at 4.61% for IMVT. The simple moving average for the last 20 days is -13.90% for IMVT stock, with a simple moving average of -16.02% for the last 200 days.
Is It Worth Investing in Immunovant Inc (NASDAQ: IMVT) Right Now?
Company’s 36-month beta value is 0.69.Analysts have differing opinions on the stock, with 11 analysts rating it as a “buy,” 7 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for IMVT is 62.23M, and currently, short sellers hold a 21.05% ratio of that floaft. The average trading volume of IMVT on November 20, 2024 was 877.35K shares.
IMVT) stock’s latest price update
Immunovant Inc (NASDAQ: IMVT) has seen a decline in its stock price by -1.14 in relation to its previous close of 25.51. However, the company has experienced a -13.84% decline in its stock price over the last five trading sessions. zacks.com reported 2024-11-08 that IMVT reports dismal second-quarter fiscal 2025 results. It is on track to initiate several studies on IMVT-1402 across various autoimmune indications.
Analysts’ Opinion of IMVT
Many brokerage firms have already submitted their reports for IMVT stocks, with Raymond James repeating the rating for IMVT by listing it as a “Outperform.” The predicted price for IMVT in the upcoming period, according to Raymond James is $36 based on the research report published on October 10, 2024 of the current year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see IMVT reach a price target of $53, previously predicting the price at $47. The rating they have provided for IMVT stocks is “Outperform” according to the report published on October 09th, 2024.
Oppenheimer gave a rating of “Outperform” to IMVT, setting the target price at $50 in the report published on March 28th of the current year.
IMVT Trading at -13.75% from the 50-Day Moving Average
After a stumble in the market that brought IMVT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -44.67% of loss for the given period.
Volatility was left at 4.61%, however, over the last 30 days, the volatility rate increased by 5.18%, as shares sank -14.80% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -15.14% lower at present.
During the last 5 trading sessions, IMVT fell by -13.84%, which changed the moving average for the period of 200-days by -31.11% in comparison to the 20-day moving average, which settled at $29.29. In addition, Immunovant Inc saw -40.14% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IMVT starting from Levine Mark S., who sale 4,361 shares at the price of $29.53 back on Oct 23 ’24. After this action, Levine Mark S. now owns 322,878 shares of Immunovant Inc, valued at $128,780 using the latest closing price.
Geffner Michael, the Chief Medical Officer of Immunovant Inc, sale 3,189 shares at $29.53 during a trade that took place back on Oct 23 ’24, which means that Geffner Michael is holding 134,971 shares at $94,171 based on the most recent closing price.
Stock Fundamentals for IMVT
Current profitability levels for the company are sitting at:
- -223.82 for the present operating margin
- 0.87 for the gross margin
The net margin for Immunovant Inc stands at -215.34. The total capital return value is set at -0.75. Equity return is now at value -92.17, with -79.97 for asset returns.
Based on Immunovant Inc (IMVT), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -5779.64.
Currently, EBITDA for the company is -269.98 million with net debt to EBITDA at 1.34. When we switch over and look at the enterprise to sales, we see a ratio of 2152.68. The receivables turnover for the company is 0.8for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.61.
Conclusion
In a nutshell, Immunovant Inc (IMVT) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
